IQVIA Holdings ((IQV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The study titled A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough aims to evaluate the effectiveness, safety, and tolerability of NOC-110. This research is significant as it targets adults suffering from chronic coughs that are either unexplained or resistant to existing treatments.
Intervention/Treatment: The study tests the drug NOC-110, an inhalation powder, administered in doses of 1mg, 3mg, and 6mg. It is designed to alleviate symptoms of chronic cough by providing a new therapeutic option.
Study Design: This is an interventional study with a randomized, sequential model. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused.
Study Timeline: The study began on July 11, 2024, with the latest update on August 8, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
Market Implications: This study update could influence IQVIA Holdings’ stock performance positively, as successful results might enhance investor confidence and market position. Competitors in the chronic cough treatment market may need to reassess their strategies if NOC-110 proves effective.
The study is ongoing, and further details are available on the ClinicalTrials portal.